Market Overview

UBS: Buy Biogen For Pipeline, M&A Potential

UBS: Buy Biogen For Pipeline, M&A Potential
Related BIIB
The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut
The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent
Gritstone Oncology Prepares Final Terms For IPO (Seeking Alpha)

Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside. 

The Rating

UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410.

The Thesis

Biogen’s existing pipeline and potential asset acquisitions through 2018 present a $45-a-share opportunity, Gould said in a Wednesday note. 

Stabilization of the biotech’s multiple sclerosis business, clarity on negative Spinraza growth and 2019 data on the aducanumab Alzheimer’s trial affirm the “core pillars” of Biogen valuation and earnings per share estimates and positively skew the risk-reward, the analyst said.

“The current share price still implies minimal (if any) value for these assets,” the analyst said. “While these are high-risk programs, they (1) all have blockbuster potential, and (2) are not in Street models — implying success for any one likely drives upside from here.”

The pipeline compounds “increasing likelihood” that Biogen buys new assets with its $37-billion in capital, Gould said. 

The analyst said he expects a 2018 focus on the midstage neurology portfolio with trial results for stroke, neuropathic pain, Parkinson’s disease and amyotrophic lateral sclerosis. The indications are presently excluded from Street models and together represent a sales opportunity between $9 billion and $17 billion, according to UBS. 

Price Action

At the time of publication, shares were set to open up 1.4 percent at $357.55.

Related Links:

Here's Why Forward Pharma Lost 30% Today

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Latest Ratings for BIIB

Aug 2018Stifel NicolausReinstatesBuy
Jul 2018UBSMaintainsBuyBuy
Jul 2018BarclaysMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: alzheimer's treatment Carter GouldAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (BIIB)

View Comments and Join the Discussion!

ETFs: Focusing On Financials In February

Benzinga's Top Upgrades, Downgrades For January 31, 2018